InvestorsObserver
×
News Home

Actinium Pharmaceuticals Inc (ATNM) Stock: Buy, Hold, or Sell?

Tuesday, December 29, 2020 11:00 AM | InvestorsObserver Analysts

Mentioned in this article

Actinium Pharmaceuticals Inc (ATNM) Stock: Buy, Hold, or Sell?

InvestorsObserver is giving Actinium Pharmaceuticals Inc (ATNM) an Analyst Rating Rank of 79, meaning ATNM is ranked higher by analysts than 79% of stocks. The average projection by analysts for ATNM is $38.333 over the next 12 months and analyst’s classify the stock as a Strong Buy

Overall Score - 5
Wall Street analysts are rating ATNM a Strong Buy today. Find out what this means to you and get the rest of the rankings on ATNM!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.

InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Actinium Pharmaceuticals Inc Stock Today?

Actinium Pharmaceuticals Inc (ATNM) stock is lower by -23.6% while the S&P 500 is up 0.11% as of 10:55 AM on Tuesday, Dec 29. ATNM is lower by -$2.53 from the previous closing price of $10.72 on volume of 1,470,501 shares. Over the past year the S&P 500 has gained 16.09% while ATNM is up 20.44%. ATNM lost -$2.59 per share the over the last 12 months.

Click Here to get the full report on Actinium Pharmaceuticals Inc (ATNM) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App